ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

According to findings presented at the 2017 World Conference on Lung Cancer, the potent and selective inhibitor of ROS1 and TRKentrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with ROS1 fusion-positive advanced non–small cell lung cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.